Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY2021 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, May 25, 2021
Slide 1: Investor Presentation Q4FY21
Investor Presentation Q4FY21 May 25, 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q4FY21 and FY21
Key Highlights of Q4FY21 and FY21 Healthy performance in a challenging year • Revenue from Operations grew by 6.2% YoY during the financial year, accompanied by 420bps expansion in EBITDA margin to 21.9% and Net Profit growth of 40.6% YoY • During the Quarter, Revenue from Operations grew by 7.0% Yo
Slide 4: Key Financial Highlights – Q4FY21 (Consolidated)
Key Financial Highlights – Q4FY21 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 14,732 12,576 21,922 20,490 Q4FY20 Q4FY21 International sales 7,523 6,907 Q4FY20 Q4FY21 Q4FY20 Q4FY21
Slide 5: Key Financial Highlights – Q4FY21 (Consolidated)
Key Financial Highlights – Q4FY21 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 12,492 11,546 3,030 2,911 56.3% 57.0% 14.8% 13.3% Q4FY20 Q4FY21 Q4FY20 Q4FY21 PBT (before Minority Interest) PAT (after Minority Interest) 2,400 2,582 1,888 2,353 Q4FY20 Q4FY21
Slide 6: Key Financial Highlights – FY21 (Consolidated)
Key Financial Highlights – FY21 (Consolidated) Particulars (₹ mn) FY21 FY20 YoY growth Revenue from Operations 88,650 83,444 6.2% Gross Profit 53,666 49,994 7.3% Gross Profit margin 60.5% 59.9% EBITDA 19,424 14,734 31.8% EBITDA margin 21.9% 17.7% PBT 18,421 12,598 46.2% PBT margin 20.8% 15.1% PAT (A
Slide 7: India Business
India Business India Business: Q4FY21 Sales of ₹ 14,732 million (17.1% YoY growth) • India sales contributed 68.1% to total sales in Q4FY21 • Company witnessed good recovery in the second half of the financial year compared to YoY decline in the first half • Company’s Trade Generic business delivere
Slide 8: Secondary Sales Performance
Secondary Sales Performance Company’s India business registered healthy recovery in the second half of FY21 compared to YoY decline in the first half Alkem’s Secondary Sales Growth YoY Therapy segment Q1FY21 Q2FY21 Q3FY21 Q4FY21 FY21 Anti-infectives -22.1% -12.2% -3.9% -0.5% -9.5% Gastro Intestinal
Slide 9: US Business
US Business US Business: Q4FY21 Sales of ₹ 5,435 million (YoY decline of 10.4%) • US sales contributed 25.1% to total sales in Q4FY21 • Company’s US sales doubled in four years through FY17 to FY21 registering a CAGR of 19.5% led by new product launches and market share gain in existing products • I
Slide 10: US Business
US Business EIR for all the six facilities inspected by the US FDA Facility Capability Last inspection Status post last inspection St. Louis (US) Formulation January - February 2020 EIR# received in May 2020 Baddi (India) Formulation February 2020 EIR# received in March 2020 Daman (India) Formulatio
Slide 11: Other International Business
Other International Business Other International Business: Q4FY21 Sales of ₹ 1,472 million (1.2% YoY growth) • Other International Market sales contributed 6.8% to total sales in Q4FY21 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Chile, Kazakhsta
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on March 31, 2021 Non-Institution, 22.22% Promoter & Promoter Group, 60.16% Institution, 17.62% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodi
Slide 13: Thank You
Thank You For further information or queries, please contact Gagan Borana Investor Relations – Alkem Laboratories Ltd. Tel: +91 22 3982 9960 E-mail: [email protected]